Non-EPI Vaccine Hesitancy among Chinese Adults: A Cross-Sectional Study

Jianli Wang 1,2, Yan Zhang 1,2, Sigui Long 1,2, Xin Fu 1,2, Xiaoxuan Zhang 1,2, Shuangyu Zhao 1,2, Shixin Xiu 3, Xuwen Wang 3, Bing Lu 3 and Hui Jin 1,2,*

1 Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China; 213171070@seu.edu.cn (J.W.); 213180365@seu.edu.cn (S.L.); 213180456@seu.edu.cn (X.F.); 213181280@seu.edu.cn (X.Z.); 213181074@seu.edu.cn (S.Z.)
2 Key Laboratory of Environmental Medicine Engineering, School of Public Health, Southeast University, Ministry of Education, Nanjing 210009, China
3 Wuxi Center for Disease Control and Prevention, Wuxi 214023, China; wxxdcss@163.com (S.X.); wxmsgwang@163.com (X.W.); Lub19661023@163.com (B.L.)
* Correspondence: jinhuihld@seu.edu.cn; Tel.: +86-025-8327-2572; Fax: +86-825-8327256

Abstract: Vaccination against coronavirus disease 2019 (COVID-19) is paramount to curtailing the pandemic. However, the impact of the Non-Expanded Program on Immunization (non-EPI) and COVID-19 vaccine hesitancy on vaccine uptake among Chinese adults remain unclear. This study was an online survey performed in Eastern, Central, and Western China between February 2021 and March 2021 using proportional sampling (n = 7381). Adults aged ≥ 18 years were included, especially younger people (aged < 65). Vaccine hesitancy was assessed using the 3C model and relative scales; logistic regression was used to explore the factors affecting vaccination uptake; structural equation modeling was used to evaluate the correlations between variables. Overall, 67.6% and 24.7% of adults reported vaccine hesitancy toward the non-EPI and COVID-19 vaccines, respectively. Participants (66.3%) reported taking the vaccine mainly based on recommendations from medical staff. Vaccine-hesitant participants (60.5%) reported a fear of side effects as the deciding factor in vaccine rejection. Vaccine hesitancy interacted negatively with confidence (β = −0.349, p < 0.001) and convenience (β = −0.232, p < 0.001), and positively with complacency (β = 0.838, p < 0.001). Nonmedical personnel, adults who had previously received the influenza vaccine, and older people had lower vaccine hesitancy than their counterparts. Most Chinese adults have non-EPI but not COVID-19 vaccine hesitancy. Vaccine safety remains a concern.

Keywords: Chinese adults; vaccine hesitancy; non-EPI vaccine; COVID-19 vaccine

1. Introduction

Vaccine hesitancy involves denying or delaying vaccination when vaccination services are available while agreeing to receive other medical services [1]. Vaccine hesitancy affects vaccination coverage and may cause severe public health consequences. For example, global media misinformation about adverse reactions to the human papilloma virus (HPV) vaccine in 2013 resulted in the rates of this vaccine uptake dropping from 70% to 0.6% in Japan [2]. The belief that the measles, mumps, and rubella vaccines cause autism led to low vaccine coverage in Sweden [3]. Anti-vaccination campaigns in Malaysia have created high rates of vaccine hesitancy [4]. Similarly, Chinese people tend to delay or refuse vaccinations due to negative information about the risks of vaccines [5]. The World Health Organization identified vaccine hesitancy as among the top 10 global health threats in 2019 [6].

To address vaccine hesitancy, a “3Cs” model was proposed in 2011 [7], highlighting complacency, convenience, and confidence as the key drivers. Other relevant factors can fall into three groups [6]: social factors (history, society, culture, environment, health
systems/institutions, economy, and politics); individual and group factors (personal views on vaccines); and direct factors associated with vaccines or vaccinations. Especially, age is one of the most important factors in view of decreased immunity and existing chronic diseases, and older adults tend to be more vulnerable to acquiring or developing more severe illnesses, along with life-threatening complications \cite{8,9}. However, these illnesses can be prevented via vaccination programs.

Mass vaccinations with high coverage play an important role in disease outbreak control and prevention, helping curtail infection spread and build herd immunity. However, recent surveys have shown a high level of vaccine hesitancy worldwide \cite{10}. A cross-sectional survey in the United States \cite{11} and the UK \cite{12} showed that the COVID-19 vaccine hesitation rates were about 50% and 40%, respectively. In fact, the rate of coronavirus disease 2019 (COVID-19) vaccine hesitancy in China is 20% \cite{13,14}. Moreover, a longitudinal follow-up study between March and November to December 2020 showed that the willingness to receive a vaccination declined remarkably in China \cite{15}. However, few studies have investigated the degree of COVID-19 vaccination hesitancy in the Chinese population since the outbreak of this disease; in addition, the factors driving vaccination hesitancy remain unclear. Despite the progress in COVID-19 vaccine efficacy and availability, vaccination hesitancy may reduce the effectiveness of the global immunization program.

This study aimed to examine the rate of vaccine hesitancy among adults in Eastern, Central, and Western China using online questionnaires; the factors associated with this hesitancy were also examined. This study focused on the Non-Expanded Program on Immunization (non-EPI) and COVID-19 vaccines. The present findings may inform immunization guidelines and policies, helping to reduce the rates of vaccination hesitancy and increase those of vaccination uptake.

2. Materials and Methods

This study was conducted in 31 provinces of Eastern, Central, and Western China (Supplementary Figure S1) between 9 February 2021 and 13 March 2021 using online questionnaires. We cooperated with some local disease control centers and hospitals. Moreover, our survey team members were distributed in almost all provinces, and each member collected a certain number of online questionnaires locally. Handy sampling was adopted; proportional sampling was performed per region. Sampling was conducted according to the population ratio of each province in the three regions and conducted in the form of an online anonymous survey through Questionnaire Star (the most widely used questionnaire platform in China). A total of 8256 questionnaires were collected in this study, and 7318 valid questionnaires were finally included in the study. Only Chinese adults aged ≥18 years were included. The following formula was used to calculate the sample size:

\[
N_{\text{min}} = \text{deff} \times \frac{Z^2 \times (1-\alpha/2) \times p \times (1-p)}{d^2}
\]

Type I error (\(\alpha\)) was set to 0.05, precision (\(d\)) value was set to 0.04, and the desired effect size (\(\text{deff}\)) was set to 2 \cite{14,15}. Vaccine hesitancy rate (95% confidence interval (CI)) (\(p\)) was conservatively set at 50%. The minimum sample size was estimated as 2081. For this cross-sectional survey, we set the sample size to 2200 people under the conditions of shedding and deletion. We estimated the required sample size to be 6600 (3 × 2200) participants, based on these calculations.

2.1. Measures

The questionnaire consisted of three parts: demographic characteristics, non-EPI vaccine hesitancy, and COVID-19 vaccination willingness.

The demographic characteristics of interest were age, gender, ethnicity, place of residence, education, occupation, whether engaged with healthcare-related industries or not, annual family income, social contacts (including the number of people in residence and the
number of daily contacts), and health behaviors, including self-reported health status and
the history of influenza vaccination.

Based on the “3C” model and other models [16], a vaccine hesitancy survey scale was
created comprising 15 items (Supplementary Table S1). In the end, 11 items were included
(Supplementary Table S2) based on a reliability and validity analysis [17].

The COVID-19 vaccination willingness questionnaire included the willingness to
get vaccinated, the causes of vaccination, and adverse reactions after vaccination. The
willingness to vaccinate was measured using the following question: “Are you willing to
take the COVID-19 vaccine?” The answers were “yes”, “not sure”, and “no.”

2.2. Statistical Analysis

Critical ratio, Spearman rank correlation coefficient, and internal consistency anal-
ysis were used to screen the survey items. Internal consistency reliability and split-half
reliability were used to test the scale reliability; split-half reliability was tested using the
odd–even method.

Content and construct validity were examined. Construct validity was evaluated by
a confirmatory factor analysis, which examined whether the dimensions of a scale were
consistent with the corresponding theoretical framework. An exploratory factor analysis
was used with the adjusted scale. The maximum coefficient of variation method was
used for orthogonal rotation (varimax) in the factor load matrix analysis (Supplementary
Table S3). Moreover, a confirmatory factor analysis showed that the model with 11 items
had a relatively better goodness-of-fit (Supplementary Table S4), with meaningful Cron-
bach’s alpha values for the confidence, complacency, and convenience dimensions and the
overall scale (Supplementary Table S5); consequently, the 11-item scale was used [18].

SPSS (version 23.0, IBM, Armonk, NY, USA) and Microsoft Excel (version 2019, Mi-
crosoft Corp., Redmond, WA, USA) were used for the statistical analysis. For continuous
variables, a single-factor analysis of variance or independent sample t-test were used
for between-group comparisons of variables that met the normality of distribution and
homogeneity of variance assumptions; the nonparametric rank sum test was used when
these assumptions were not met. For categorical variable comparisons, the chi-square or
Fisher’s exact tests were used. Odds ratios (ORs) and 95% confidence intervals (CIs) were
used to explore the factors affecting COVID-19 vaccine uptake willingness using a logistic
regression analysis. Structural equation modeling (SEM) was used to further study the
factors affecting vaccine hesitancy (Supplementary Table S6). Statistical significance was
set as two-sided p-values of <0.05. In this analysis, responses referring to “hesitation” and
“uncertainty” were combined into a single “hesitation” item.

2.3. Factors Affecting Vaccine Hesitancy

Amos software (version 24.0, IBM, Armonk, NY, USA) was used to establish the 3C
dimensions of vaccine hesitancy in a multifactorial SEM. We constructed a variable set
based on the survey data and the “3C model.” “Confidence” included five items (Q1, Q2,
Q3, Q4, and Q6); “complacency” included three items (Q8, Q9, and Q10); and “convenience”
included Q12 and some items of Q13 and Q14. “Vaccine hesitation” included Q16 items.
The assignment tables are presented in Table 1. The obtained model was modified through
an adaptation test and Delphi Expert Consultation method [19]. Finally, we conducted a
fractional analysis.
Table 1. Variables assignment for the structural equation model of a vaccine.

| Variable Meaning                                                                 | Assignment | Referenced Variable |
|----------------------------------------------------------------------------------|------------|---------------------|
| Q1. Generally, I think the vaccine is safe                                       | 1 = very agree; 2 = agree; 3 = uncertain; 4 = disagree; 5 = very disagree |
| Q2. Generally, I think the vaccine is effective                                  |            |                     |
| Q3. I think vaccines are very important for my health                            |            |                     |
| Q4. Generally, I think the whole chain (whole process, from production to        |            |                     |
| vaccination) management of vaccine is safe and effective                          |            |                     |
| Q6. Please evaluate your trust in the vaccination information provided by the    |            |                     |
| government                                                                       |            |                     |
| Q8. In my opinion, immunity from natural diseases is better than vaccination     |            |                     |
| Q9. Because of the low risk of disease, there is no need for vaccination         |            |                     |
| Q10. Even if I have a disease, I can resist it, so I don’t need a vaccine        |            |                     |
| Q12. Generally, it’s very convenient and time-consuming for me to get vaccinated |            |                     |
| Q13. Generally, I was able to get the vaccine I wanted                           |            |                     |
| Q14. Generally, I can afford the vaccine                                         |            |                     |

3. Results

A total of 7318 out of 8000 respondents were included in this study. Among them, 682 participants were excluded due to data quality concerns. Overall, 70.9% of the participants were younger people aged 18–35 years old, and older people merely accounted for very small proportion (Table 2); over 75% and 34.5% of the participants had a college or equivalent degree and an annual family income in the range of 50,000–100,000 RMB, respectively. Among the participants, 2616 (35.7%) were engaged with the enterprise/business/service industry, while 2386 (32.6%) were employees of the healthcare sector (including doctors, nurses, public health physicians, and pharmacy technicians, among others). Most (86.3%) respondents reported being in good health.

Table 2. Non-EPI vaccine hesitancy and COVID-19 vaccine hesitancy among participants with different demographics.

| Demographic Characteristics | Number | Proportion (%) | Non-EPI Vaccine Hesitancy | COVID-19 Vaccine Hesitancy |
|-----------------------------|--------|----------------|---------------------------|---------------------------|
|                             |        |                | Yes Frequency (%)         | No Frequency (%)          | p Value | Yes Frequency (%) | No Frequency (%) | p Value |
| Age, years                  |        |                |                           |                           |         |                   |                   |         |
| 18–25                       | 2409   | 32.90          | 1771 (73.5)               | 638 (26.5)                | <0.001  | 600 (24.9)        | 1809 (75.1)      | <0.001  |
| 26–35                       | 2784   | 38.00          | 1814 (65.2)               | 970 (34.8)                | 615 (22.1) | 2169 (77.9)      |                   |         |
| 36–45                       | 1264   | 17.30          | 811 (64.2)                | 453 (35.8)                | 320 (25.3) | 944 (74.7)       |                   |         |
| ≥46                         | 861    | 11.80          | 549 (63.8)                | 312 (36.2)                | 272 (31.6) | 589 (68.4)       |                   |         |
| Gender                      |        |                |                           |                           |         |                   |                   |         |
| Male                        | 3565   | 48.70          | 2382 (66.8)               | 1183 (33.2)               | 0.178   | 741 (20.8)        | 2824 (79.2)      | <0.001  |
| Female                      | 3753   | 51.30          | 2563 (68.3)               | 1190 (31.7)               | 1066 (28.4) | 2687 (71.6)      |                   |         |
| Nationality                 |        |                |                           |                           |         |                   |                   |         |
| Han                         | 6979   | 95.40          | 4714 (67.5)               | 2265 (32.5)               | 0.819   | 1719 (24.6)       | 5260 (75.4)      | 0.580   |
| Non-Han                     | 339    | 4.60           | 231 (68.1)                | 108 (31.9)                | 88 (26.0) | 251 (74.0)       |                   |         |
| Place of residence          |        |                |                           |                           |         |                   |                   |         |
| East                        | 4292   | 58.60          | 2938 (68.5)               | 1354 (31.5)               | 0.160   | 1160 (27.0)       | 3132 (73.0)      | <0.001  |
| Central                     | 1559   | 21.30          | 1034 (66.3)               | 525 (33.7)                | 277 (17.8) | 1282 (82.2)      |                   |         |
| West                        | 1467   | 20.00          | 973 (66.3)                | 494 (33.7)                | 370 (25.2) | 1097 (74.8)      |                   |         |
Table 2. Cont.

| Demographic Characteristics | Number | Proportion (%) | Non-EPI Vaccine Hesitancy | COVID-19 Vaccine Hesitancy |
|-----------------------------|--------|----------------|---------------------------|---------------------------|
|                             |        |                | Yes Frequency (%) | No Frequency (%) | p Value | Yes Frequency (%) | No Frequency (%) | p Value |
|                             |        |                | (%)                | (%)                 |         | (%)                | (%)                 |         |
| Education level             |        |                |                    |                     |         |                    |                     |         |
| ≤Junior high school         | 436    | 6.00           | 310 (71.1)          | 126 (28.9)          | 0.041   | 103 (23.6)          | 333 (76.4)          | <0.001  |
| High school or equivalent   | 1193   | 16.30          | 786 (65.9)          | 407 (34.1)          |         | 246 (20.6)          | 947 (79.4)          |         |
| College or equivalent       | 4692   | 64.10          | 3147 (67.1)         | 1545 (32.9)         | 1148 (24.5) | 3544 (75.5) |         |         |
| ≥Master’s degree            | 997    | 13.60          | 702 (70.4)          | 295 (29.6)          |         | 310 (31.1)          | 687 (68.9)          |         |
| Occupation                  |        |                |                    |                     |         |                    |                     |         |
| Government agencies and institutions | 1681 | 23.00          | 1088 (64.7)         | 593 (35.3)          | <0.001  | 415 (24.7)          | 1266 (75.3)         | <0.001  |
| Enterprise/business/service industry | 2616 | 35.70          | 1724 (65.9)         | 892 (34.1)          |         | 561 (21.4)          | 2055 (78.6)         |         |
| Agricultural/forestry/animal husbandry/fishery/water conservancy production personnel | | | | | | | | |
| Soldier                     | 765    | 10.50          | 526 (68.8)          | 239 (31.2)          |         | 125 (16.3)          | 640 (83.7)          |         |
| Full-time student           | 1326   | 18.10          | 981 (74.0)          | 345 (26.0)          | 402 (30.3) | 924 (69.7) |         |         |
| Other                       | 807    | 11.00          | 566 (70.1)          | 241 (29.9)          |         | 291 (36.1)          | 516 (63.9)          |         |
| Healthcare occupation       |        |                |                    |                     |         |                    |                     |         |
| Yes                         | 2386   | 32.60          | 1666 (69.8)         | 720 (30.2)          | 0.004   | 402 (16.8)          | 1984 (83.2)         | <0.001  |
| No                          | 4932   | 67.40          | 3279 (66.5)         | 1653 (33.5)         |         | 1405 (28.5)        | 3527 (71.5)         |         |
| Annual family income (RMB 10,000) | | | | | | | | |
| <5                          | 1481   | 20.20          | 1045 (70.6)         | 436 (29.4)          | 0.005   | 333 (22.5)          | 1148 (77.5)         | <0.001  |
| 5–10                        | 2524   | 34.50          | 1656 (65.6)         | 868 (34.4)          |         | 587 (23.3)          | 1937 (76.7)         |         |
| 11–15                       | 1738   | 23.70          | 1157 (66.6)         | 581 (33.4)          | 359 (20.7) | 1379 (79.3) |         |         |
| ≥16                         | 1575   | 21.50          | 1087 (69.0)         | 488 (31.0)          |         | 528 (33.5)          | 1047 (66.5)         |         |
| Number of people in residence | | | | | | | | |
| 1                           | 477    | 6.50           | 329 (69.0)          | 148 (31.0)          | 0.364   | 121 (25.4)          | 356 (74.6)          | 0.752   |
| 2–5                         | 6466   | 88.40          | 4374 (67.6)         | 2092 (32.4)         |         | 1599 (24.7)        | 4867 (75.3)         |         |
| ≥6                          | 375    | 5.10           | 242 (64.5)          | 133 (35.5)          |         | 87 (23.2)           | 288 (76.8)          |         |
| Number of contacts per day  |        |                |                    |                     |         |                    |                     |         |
| 1–10                        | 4684   | 64.00          | 3176 (67.8)         | 1508 (32.2)         | 0.002   | 1224 (26.1)        | 3460 (73.9)         | 0.001   |
| 11–20                       | 1824   | 24.90          | 1264 (69.3)         | 560 (30.7)          |         | 400 (21.9)          | 1424 (78.1)         |         |
| ≥21                         | 810    | 11.10          | 505 (62.3)          | 305 (37.7)          |         | 183 (22.6)          | 627 (77.4)          |         |
| Self-reported health        |        |                |                    |                     |         |                    |                     |         |
| Very good                   | 3508   | 47.90          | 2275 (64.9)         | 1233 (35.1)         | <0.001  | 614 (17.5)          | 2894 (82.5)         | <0.001  |
| Good                        | 2813   | 38.40          | 1929 (66.8)         | 884 (31.4)          |         | 848 (30.1)          | 1965 (69.9)         |         |
| Common                      | 921    | 12.60          | 688 (74.7)          | 233 (25.3)          | 320 (34.7) | 601 (65.3) |         |         |
| Bad                         | 56     | 0.80           | 43 (76.8)           | 13 (23.2)           | 20 (35.7) | 36 (64.3) |         |         |
| Very bad                    | 20     | 0.30           | 10 (50.0)           | 10 (50.0)           | 5 (25.0) | 15 (75.0) |         |         |
| Have you ever been obtained the influenza vaccination? | | | | | | | | |
| Yes                         | 2293   | 31.30          | 1398 (61.0)         | 895 (39.0)          | <0.001  | 223 (9.7)          | 2070 (90.3)         | <0.001  |
| No                          | 5025   | 68.70          | 3547 (70.6)         | 1478 (29.4)         |         | 1584 (31.5)        | 3441 (68.5)         |         |
| Total                       | 7318   | 100.00         | 4945 (67.6)         | 2373 (32.4)         |         | 1807 (24.7)        | 5511 (75.3)         |         |
3.1. Non-EPI Vaccine Willingness among Adults

A total of 4945 (67.6%) participants reported hesitancy regarding the non-EPI vaccines (Table 2); in addition, 72.10% of the participants declared that “If family, friends, or doctors recommend vaccines to me, I’d be inclined to be vaccinated” (Figure 1a). Meanwhile, individual convictions (47.1%) and parental influence affected the decision to vaccinate (Figure 1b). The decision to receive a non-EPI vaccine was determined by sources of information, such as doctors (66.3%), family or friends (55.8%), and social media (30.1%; Figure 2). The findings from the Likert scale (Supplementary Table S1) indicated that over 60% of adults strongly agreed/trusted or agreed/trusted items Q1–Q7 and Q12–Q14; conversely, a quite low percentage (approximately 30%) showed agreement/trust in items Q9 and Q10 (Supplementary Figure S2).

Figure 1. Impact of peer groups on vaccination attitudes. (a) Attitudes towards non-EPI vaccinations recommended by family, friends, or doctors. (b) Impact of family members on non-EPI vaccination decisions (N = 7318).

Figure 2. Primary sources of information on non-EPI vaccinations (N = 7318).
3.2. Willingness to Take the COVID-19 Vaccine among Adults

A total of 75.3% of the participants reported a willingness to accept the COVID-19 vaccine (Figure 3a), quoting “protecting others” (86.36%), “preventing infection” (58.9%), and believing that the “COVID-19 vaccine is effective” (54.70%) as the key motivators (Figure 4a). However, among 24.7% of the participants who declared vaccination unwillingness/refusal (Figure 3a), the most frequently (60.5%) cited reason was “concern about side effects and safety” (Figure 4b). A total of 26.60% of the participants had received the COVID-19 vaccine (Figure 3b); among them, 58% reported no adverse events, while 19.2% and 18.5% of the vaccinated participants reported symptoms of hypodynamia and localized pain, respectively (Supplementary Figure S3).

Figure 3. Participants declaring COVID-19 vaccination (a) intention and (b) uptake.

Figure 4. Reasons for COVID-19 vaccination (a) willingness and (b) refusal.
3.3. Factors Associated with Vaccine Hesitancy

The factors associated with vaccine hesitancy were younger age, higher education and annual income levels, lower number of daily contacts, better self-reported health status, working for sectors other than healthcare, and no history of influenza vaccination \((p < 0.05)\) (Table 2). Furthermore, higher rates of COVID-19 vaccine hesitancy were observed among women and the residents of Eastern China than among their counterparts \((p < 0.05)\).

The results of the multivariate analysis are presented in Supplementary Table S7. Participants with \(\geq 21\) daily contacts showed lower vaccine hesitancy compared with those with 1–10 daily contacts, and holders of college or equivalent degrees \((OR: 0.752, 95\% CI: 0.597–0.948, p = 0.016)\) were more willing to accept vaccinations compared with participants with junior high school and below education; soldiers \((OR: 0.635, 95\% CI: 0.56–0.719, p = 0.002)\) had lower vaccine hesitancy than those in government and institutions; compared with medical health practitioners, non-medical health practitioners \((OR: 0.547, 95\% CI: 0.371–0.807, p < 0.001)\) had lower rates of vaccine hesitancy. In contrast, higher rates of vaccine hesitancy were observed in participants with an average self-rated health status \((OR: 1.538, 95\% CI: 1.299–1.822, p < 0.001)\) and those that had never received the influenza vaccine \((OR: 1.801, 95\% CI: 1.591–2.038, p < 0.001)\), including production personnel in agriculture, forestry, animal husbandry, and fishery \((OR: 1.255, 95\% CI: 1.027–1.534, p = 0.026)\).

In addition, the participants residing in Central \((OR: 0.681, 95\% CI: 0.582–0.798, p < 0.001)\) and Western China \((OR: 0.821, 95\% CI: 0.705–0.955, p = 0.011)\) showed lower rates of COVID-19 vaccine hesitancy than those living in the eastern regions (Supplementary Table S7). Moreover, participants with \(\geq 21\) daily contacts \((OR: 0.776, 95\% CI: 0.642–0.938, p = 0.009)\) showed lower rates of COVID-19 vaccine hesitancy than their counterparts. The participants with a master’s or higher degree had a higher rate \((OR: 1.372, 95\% CI: 1.012–1.860, p = 0.041)\) of COVID-19 vaccine hesitancy than those with a junior high school or lower degree. Compared to those with a very good self-rated health status, all others with a good, common, or poor self-rated health status (except those with very poor one) were more likely to have COVID-19 vaccine hesitancy. The participants who had never received the influenza vaccine \((OR: 2.995, 95\% CI: 2.536–3.539, p < 0.001)\) and non-healthcare workers \((OR: 1.426, 95\% CI: 1.232–1.65, p < 0.001)\) showed higher rates of vaccine hesitancy than their counterparts. Moreover, higher rates of COVID-19 vaccine hesitancy were observed in adults with an annual household income of \(\geq 160,000\) RMB \((OR: 1.465, 95\% CI: 1.211–1.772, p < 0.001)\) than in those with annual household incomes of <50,000.

The 3C dimensions, path diagram, and standardized path coefficient of the SEM of adult vaccine hesitancy are shown in Figure 5. Vaccination hesitancy interacted negatively with confidence \((\beta = −0.349, p < 0.001)\) and convenience \((\beta = −0.232, p < 0.001)\) and positively with complacence \((\beta = 0.838, p < 0.001)\). Moreover, complacence correlated with convenience. Finally, older adults, non-medical health practitioners, and those with a history of influenza vaccination had lower rates of vaccine hesitancy than adults aged 18–25 years.
Multiple factors may determine vaccine hesitancy. A relatively low level of vaccine hesitancy in adults aged ≥ 25 years may be associated with individual experience and information that allows to make accurate judgments about the benefits and risks of vaccination. A higher income may also increase vaccine accessibility and convenience. Similarly, a lower vaccine hesitancy was observed among the members of the military, which might be relevant for the mobilization of groups. An atmosphere that facilitates vaccination may help improve the acceptance of vaccines by decreasing individual complacency [21]. A previous study showed that peer group support and mobilization from leaders may improve public trust in vaccines [22]. Participants with college or junior college degrees showed relatively lower rates of vaccine hesitancy than those who were less educated. In addition, people reportedly in good general health were likely to take vaccines for health protection. Adults with a number of daily contacts of ≥ 21 were less likely to refuse the non-EPI vaccines due to increased exposure to pathogens. Vaccinations boosts immunity and reduce the risk of disease.

Doctors and parents can influence attitudes toward vaccination uptake. The present study participants received their vaccination-related information mainly from doctors, family members, and friends, whose recommendations tended to increase the odds of becoming vaccinated. Physicians are among the most trusted sources of vaccine-related information [23]. However, in the present study, there was a relatively high rate of non-EPI vaccine hesitancy among medical staff, and this deserves closer examination; this finding may be associated with the improved sanitary conditions and lower risks of acquiring non-EPI vaccine-preventable diseases in this group. Vaccine hesitancy among healthcare staff has been previously reported [24,25] and should be addressed. In addition, parents play an important role in their children’s vaccination decisions. Chinese parents tend to
have more confidence in the EPI than in non-EPI vaccines, which may be associated with their faith in governmental policy [13]. Thus, enhancing the education on non-EPI vaccines among adults, including parents, may increase the rates of vaccine uptake.

Most participants were willing to be vaccinated against COVID-19 to protect others and to prevent infection, believing the available vaccines to be effective; however, some participants refused to be vaccinated due to safety concerns, including the risk of adverse events; this finding is consistent with that of a previous study [26].

The risk of infection influenced the rate of COVID-19 vaccination. Health status and daily contact number affect COVID-19 vaccine hesitancy in a similar manner to non-EPI vaccines. Healthcare staff play a leading role in increasing the uptake of COVID-19 vaccines. Medical professionals involved in the treatment of COVID-19 patients were willing to be vaccinated against COVID-19, given the immunization’s role in the prevention of the disease [27,28]. Our study revealed a majority of healthcare workers (83%) were willing to accept the COVID-19 vaccine, while only 61% of Israeli nurses were willing to get vaccinated [29]. The low acceptance of the vaccine by nurses is not conducive to improving the vaccination confidence of the public. Healthcare staff should actively recommend vaccinations to the public [16] and provide accurate information on the safety and benefits of vaccines, which may help to improve public trust in vaccination programs. Medical personnel understand the benefits of vaccinations in disease prevention, resulting in relatively high uptake rates; the attitudes of healthcare workers may help set positive social norms and attitudes toward the COVID-19 vaccine, increasing the uptake. For instance, vaccinated health workers wearing badges that read “I have received vaccination to protect you from influenza” [30] may have contributed to the reduction in the incidence rate of pneumonia and influenza in the Netherlands [31]; this approach may also support COVID-19 vaccination uptake. Medical staff can help promote vaccinations; a comprehensive system of education, training, and incentives after inoculation may increase the uptake of vaccines [32].

Uptake of the COVID-19 vaccines is reduced by public fears of side effects. The COVID-19 vaccines do not trigger any adverse reactions among most vaccinated people; meanwhile, some people reported symptoms of asthenia or local pain, which raised public concern about vaccine safety. Government health departments should construct a transparent, robust, and reasonable immunization procedure for the COVID-19 vaccines and communicate the vaccine development process to the public [33] through context-specific campaigns, addressing the key concerns. Behavior change theories, such as the Health Belief Model and social marketing [34,35], may also help improve vaccination rates. High rates of COVID-19 vaccine hesitancy were observed among women; this finding was consistent with those of studies in the American and British populations [36,37]. The impact of gender-specific interventions requires further investigation.

Education and socioeconomic status, unlike the social determinants of health, had a dual impact on vaccine hesitancy in participants of different backgrounds. Higher levels of education (master’s degree or above) were associated with a lower rate of vaccine acceptance [38,39]. Higher levels of COVID-19 vaccine hesitancy were observed in participants with graduate degrees; this finding may be associated with excessive concerns over vaccine safety in this group. In addition, compared to the residents of Western and Central China, the residents of the more economically developed eastern areas, where household incomes are relatively high, reported some reluctance toward COVID-19 vaccine uptake. The intention to receive a COVID-19 vaccine was weak, regardless of the ability to access the relevant services and cover the associated costs.

This study has some limitations. First, the use of online questionnaires may have resulted in a sampling bias. In the present sample, 70.9% of adults were aged 18–35 years; older adults were under-represented. As the age of the individuals included in the study is a significant factor of vaccine hesitancy and older people are a population with specific characteristics, a further analysis of vaccine hesitancy in older people will be seriously considered and conducted in the future. Simultaneously, this sample lacked representativeness
from some provinces; consequently, the present findings should be interpreted with caution. Second, the present study was based on self-reported information; thus, the results may be subject to self-reporting bias. Although the present findings suggest variations in the rates of COVID-19 vaccine acceptance among the residents of different parts of China, further studies are required to validate these findings, which may have resulted from the study design. Third, vaccine hesitancy and willingness are influenced by many complex factors, including timing and policy; a careful examination of the impact of survey methodology on the assessment of the attitudes toward vaccines is required. Despite these limitations, the present findings advance the understanding of vaccine hesitancy and provide guidance for interventions. The reasons behind a high level of vaccine hesitancy in non-EPI vaccines and a low level in COVID-19 vaccines among medical staff will be an important direction and hotspot for addressing vaccine hesitancy in the future.

5. Conclusions

Most Chinese adults present with non-EPI vaccine hesitancy, while some of them also present with COVID-19 vaccine hesitancy. In the present study, medical staff showed a relatively high rate of non-EPI vaccine hesitancy while a low rate of COVID-19 vaccine hesitancy, as the results showed that doctors are the main information source regarding vaccines and play a leading role in increasing the uptake of COVID-19 vaccines; greater awareness and targeted education of medical staff on disease risk and vaccine benefits may be required to increase vaccination coverage. Moreover, the present findings suggest that people who were confident and willing to receive the vaccination might not necessarily choose to be vaccinated; vaccine hesitancy was the key factor preventing people from receiving vaccinations. Interventions are required to address vaccine hesitancy and increase vaccine uptake among Chinese adults. Mass vaccination is crucial to curtailing the COVID-19 pandemic.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/vaccines9070772/s1: Supplementary Table S1. Fifteen-item Likert scale of vaccine hesitancy. Supplementary Table S2. Item selection in the development of the vaccine hesitancy scale. Supplementary Table S3. Factor-loading matrices in the exploratory factor analysis. Supplementary Table S4. The reliability of the vaccine hesitancy scale. Supplementary Table S5. Model fit indexes in the confirmatory factor analysis. Supplementary Table S6. Fitness test in the multivariate structural equation model of vaccine hesitancy among adults. Supplementary Table S7. Multivariate analysis of the factors affecting non-EPI and COVID-19 vaccine hesitancy. Figure S1. The thirty-one provinces surveyed in China. Supplementary Figure S2. Distribution of the participants’ responses to 15 items on the vaccine hesitancy scale. Supplementary Figure S3. Rates of adverse reactions to the COVID-19 vaccine.

Author Contributions: Conceptualization, J.W. and H.J.; methodology, H.J.; software, H.J.; validation, H.J. and J.W.; formal analysis, J.W., S.L., S.X. and H.J.; investigation, H.J., J.W., Y.Z., S.L., X.F., S.Z., B.L. and X.Z.; resources, H.J., J.W., Y.Z., S.L., S.Z., X.F., X.W. and X.Z.; data curation, J.W.; writing—original draft preparation, J.W., Y.Z. and S.L.; writing—review and editing, J.W., Y.Z. and S.L.; visualization, S.L., X.F. and X.Z.; supervision, H.J.; project administration, H.J. and J.W.; and funding acquisition, H.J., S.X. and B.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported by the General Program of National Natural Science Fund (No. 81573258) and COVID-19 Fund of Southeast University (No. 3225002001c1).

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee of Wuxi Center for Disease Control and Prevention (2020, No. 10).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.
Acknowledgments: We thank all the personnel for their participation in the study. We also would like to thank Qiang Wang, Tingting Cui, and Minqi Liu (Southeast University) for the technical guideline and writing—review and editing.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lane, S.; MacDonald, N.E.; Marti, M.; Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine 2018, 36, 3861–3867. [CrossRef] [PubMed]

2. Larson, H.J.; Wilson, R.; Hanley, S.; Parys, A.; Paterson, P. Tracking the global spread of vaccine sentiments: The global response to Japan’s suspension of its HPV vaccine recommendation. Hum. Vaccines Immunother. 2014, 10, 2543–2550. [CrossRef] [PubMed]

3. Jama, A.; Lindstrand, A.; Ali, M.; Butler, R.; Kulane, A. Nurses’ Perceptions Of MMR Vaccine Hesitancy In An Area With Low Vaccination Coverage. Pediatr. Health Med. Ther. 2019, 10, 177–182. [CrossRef] [PubMed]

4. Wong, L.P.; Wong, P.F.; AbuBakar, S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: The way forward for Malaysia, a Southeast Asian country. Hum. Vaccines Immunother. 2020, 16, 1511–1520. [CrossRef] [PubMed]

5. He, Q.; Wang, H.; Ma, Y.; Wang, Z.; Zhang, Z.; Li, T.; Yang, Z. Changes in parents’ decisions pertaining to vaccination of their children after the Changchun Changsheng vaccine scandal in Guangzhou, China. Vaccine 2020, 38, 6751–6756. [CrossRef] [PubMed]

6. MacDonald, N.E. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef]

7. Liu, X.-J.; Mesch, G.S. The Adoption of Preventive Behaviors during the COVID-19 Pandemic in China and Israel. Int. J. Environ. Res. Public Health 2020, 17, 7170. [CrossRef] [PubMed]

8. Haq, K.; McElhaney, J.E. Immunosenescence: Influenza vaccination and the elderly. Curr. Opin. Immunol. 2014, 29, 38–42. [CrossRef] [PubMed]

9. Krueger, P.; Amant, O.S.; Loeb, M. Predictors of pneumococcal vaccination among older adults with pneumonia: Findings from the Community Acquired Pneumonia Impact Study. BMC Geriatr. 2010, 10, 44. [CrossRef] [PubMed]

10. Wang, W.; Wu, Q.; Yang, J.; Dong, K.; Chen, X.; Bai, X.; Chen, X.; Chen, Z.; Viboud, C.; Ajelli, M.; et al. Global, regional, and national estimates of target population sizes for covid-19 vaccination: Descriptive study. BMJ 2020, 371, m4704. [CrossRef] [PubMed]

11. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes toward a potential SARS-CoV-2 vaccine: A survey of US adults. Ann. Intern. Med. 2020, 173, 964–973. [CrossRef] [PubMed]

12. Sherman, S.M.; Smith, L.E.; Sim, J.; Amlot, R.; Cutts, M.; Dasch, H.; Rubin, G.J.; Sevdalis, N. COVID-19 vaccination intention in the UK: Results from the COVID-19 vaccination acceptance study (CoVAccS), a nationally representative cross-sectional survey. Hum. Vaccines Immunother. 2021, 17, 1612–1621. [CrossRef] [PubMed]

13. Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [CrossRef] [PubMed]

14. Lin, Y.; Hu, Z.; Zhao, Q.; Alias, H.; Danaee, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. PLoS Negl. Trop. Dis. 2020, 14, e0008961. [CrossRef] [PubMed]

15. Wang, J.; Lu, X.; Lai, X.; Lyu, Y.; Zhang, H.; Fenghuang, Y.; Jing, R.; Li, L.; Yu, W.; Fang, H. The Changing Acceptance of COVID-19 Vaccination in Different Epidemic Phases in China: A Longitudinal Study. Vaccines 2021, 9, 719. [CrossRef] [PubMed]

16. Freeman, D.; Loe, B.S.; Chadwick, A.; Vaccari, C.; Waite, F.; Rosenbrock, L.; Jenner, L.; Petit, A.; Lewandowsky, S.; Vanderslott, S.; et al. COVID-19 vaccine hesitancy in the UK: The Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol. Med. 2020, 11, 1–15. [CrossRef]

17. Wyatt, J. When to Use Web-Based Surveys. J. Am. Med Inform. Assoc. 2000, 7, 426–430. [CrossRef] [PubMed]

18. Eysenbach, G. Improving the quality of web surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). J. Med. Internet Res. 2000, 4, e123. [CrossRef] [PubMed]

19. Choi, M.J.; Choi, W.S.; Seong, H.; Choi, J.Y.; Kim, J.-H.; Park, H.; Lee, H.; Kim, N.J.; et al. Developing a Framework for Pandemic COVID-19 Vaccine Allocation: A Modified Delphi Consensus Study in Korea. J. Korean Med. Sci. 2021, 36, e166. [CrossRef] [PubMed]

20. Wang, C.; Han, B.; Zhao, T.; Liu, H.; Liu, B.; Chen, L.; Xie, M.; Liu, J.; Zheng, H.; Zhang, S.; et al. Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study. Vaccine 2021, 39, 2833–2842. [CrossRef] [PubMed]

21. Kumar, D.; Chandra, R.; Mathur, M.; Samdariya, S.; Kapoor, N. Vaccine hesitancy: Understanding better to address better. Isr. J. Health Policy Res. 2016, 5, 1–8. [CrossRef] [PubMed]

22. Bogart, L.M.; Ojikutu, B.O.; Tyagi, K.; Klein, D.J.; Mutchler, M.G.; Dong, L.; Lawrence, S.J.; Thomas, D.R.; Kellman, S. COVID-19 Related Medical Mistrust, Health Impacts, and Potential Vaccine Hesitancy Among Black Americans Living With HIV. J Acquir. Immune Defic. Syndr. 2021, 86, 200–207. [CrossRef] [PubMed]

23. Horne, Z.; Powell, D.; Hummel, J.E.; Holyoak, K. Countering antivaccination attitudes. Proc. Natl. Acad. Sci. USA 2015, 112, 10321–10324. [CrossRef] [PubMed]

24. Mitton, H.; Mercier, H. Cognitive Obstacles to Pro-Vaccination Beliefs. Trends Cogn. Sci. 2015, 19, 633–636. [CrossRef] [PubMed]

25. Zizzo, J. The Missing Link in the Covid-19 Vaccine Race. Hum. Vaccines Immunother. 2021, 17, 1326–1328. [CrossRef] [PubMed]
26. Carter, S. Humanitarian Programme Recommendations for COVID-19 Based on Social Sciences Evidence from the DRC Ebola Outbreak Response, CELLULE D’ANALYSE EN SCIENCES SOCIALES | CASS. 2020. Available online: https://reliefweb.int/report/world/social-science-support-covid-19-lessons-learned-brief-3-humanitarian-programme.

27. Opel, D.J.; Diekema, D.S.; Lee, N.R.; Marcuse, E.K. Social Marketing as a Strategy to Increase Immunization Rates. Arch. Pediatr. Adolesc. Med. 2009, 163, 432–437. [CrossRef]

28. Lin, L.; Sun, R.; Yao, T.; Zhou, X.; Harbarth, S. Factors influencing inappropriate use of antibiotics in outpatient and community settings in China: A mixed-methods systematic review. BMJ Glob. Health 2020, 5, e003599. [CrossRef] [PubMed]

29. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrahi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. Eur. J. Epidemiol. 2020, 35, 775–779. [CrossRef]

30. Nguyen, K.H.; Srivastav, A.; Razzaghi, H.; Williams, W.; Lindley, M.C.; Jørgensen, C.; Abad, N.; Singleton, J.A. COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination—United States, September and December 2020. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 217–222. [CrossRef]

31. Wilson, R.; Zaytseva, A.; Bocquier, A.; Nokri, A.; Fressard, L.; Chamboredon, P.; Bernardi, S.; Dubé, E.; Verger, P. Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France. Vaccine 2020, 38, 1144–1151. [CrossRef] [PubMed]

32. Di Martino, G.; Di Giovanni, P.; Di Girolamo, A.; Scampoli, P.; Cedrone, F.; D'Addezio, M.; Meo, F.; Romano, F.; Di Sciascio, M.B.; Staniscia, T. Knowledge and Attitude towards Vaccination among Healthcare Workers: A Multicenter Cross-Sectional Study in a Southern Italian Region. Vaccines 2020, 8, 248. [CrossRef] [PubMed]

33. Iten, A.; Bonfillon, C.; Bouvard, T.; Siegrist, C.-A.; Pittet, D. P037: Nosocomial influenza prevention using multi-modal intervention strategies; 20-years of experience. Antimicrob. Resist. Infect. Control. 2013, 2, P37. [CrossRef]

34. Riphagen-Dalhuisen, J.; Burgerhof, J.G.; Frijhoff, H.J.; van der Geest-Blankert, A.D.; Danhof-Pont, M.B.; de Jager, H.J.; Bos, A.A.; Smeets, E.E.; de Vries, M.J.; Gallee, P.M.; et al. Hospital-Based cluster randomised controlled trial to assess effects of a multi-faceted programme on influenza vaccine coverage among hospital healthcare workers and nosocomial influenza in the Netherlands, 2009 to 2011. Eurosurveillance 2013, 18, 20512. [CrossRef]

35. Sun, S.; Lin, D.; Operario, D. Interest in COVID-19 vaccine trials participation among young adults in China: Willingness, reasons for hesitancy, and demographic and psychosocial determinants. Prev. Med. Rep. 2021, 22, 101350. [CrossRef] [PubMed]

36. Rashid, H.; Yin, J.K.; Ward, K.; King, C.; Seale, H.; Booy, R. Assessing Interventions To Improve Influenza Vaccine Uptake Among Health Care Workers. Health Aff. 2016, 35, 284–292. [CrossRef]

37. Bish, A.; Michie, S. Demographic and attitudinal determinants of protective behaviours during a pandemic: A review. Br. J. Health Psychol. 2010, 15, 797–824. [CrossRef]

38. Bish, A.; Yardley, L.; Nicoll, A.; Michie, S. Factors associated with uptake of vaccination against pandemic influenza: A systematic review. Vaccine 2011, 29, 6472–6484. [CrossRef]